TrialSignal
Clinical trial intelligence report
A Double-blind Comparative Study of the Efficacy and Safety of E3810 10mg Once and Twice Daily in Maintenance Therapy for PPI Resistant Gastroesophageal Reflux Disease Patients
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jul 28, 2026
Report code
NCT02135107-Jul 28, 2026
NCT ID
NCT02135107
Status
COMPLETED
Phase
PHASE3
Sponsor
Eisai Co., Ltd.
Executive brief
Investment-Ready Snapshot
A Double-blind Comparative Study of the Efficacy and Safety of E3810 10mg Once and Twice Daily in Maintenance Therapy for PPI Resistant Gastroesophageal Reflux Disease Patients is a PHASE3 clinical asset sponsored by Eisai Co., Ltd. in Gastroesophageal Reflux Disease. SEO and diligence focus: Rabeprazole, Rabeprazole, Rabeprazole, Rabeprazole, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT02135107
Indication
Gastroesophageal Reflux Disease
Modality
small molecule
Target
Rabeprazole, Rabeprazole, Rabeprazole, Rabeprazole
Intervention
Rabeprazole, Rabeprazole, Rabeprazole, Rabeprazole
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.